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Introduction: Human epidermal growth factor receptor 2 (Her2) is the tyrosine kinase 
growth receptor encoded by Her2 proto-oncogene. Her-2/neu markers are considered an 
unfavorable prognosis factor, and its high expression is indicative of high metastatic tumor capacity. 
Expressed Her2 protein undergoes dimerization, resulting in degradation of intracellular 
and extracellular domain of receptor and extracellular domain releases into intercellular 
environment. Thus, the extracellular domain of the Her-2/neu receptor circulating in the 
bloodstream can be detected and measured in the serum. This feature formed the basis for the 
development of immunoassay systems for detection of soluble Her-2/neu in serum. The screening 
study of population can be carried out using enzyme linked immunosorbent assay, which is based 
on the expression and offers high sensitivity and high specificity of detection. 
Methods: The "sandwich" version of ELISA was performed on the basis of monoclonal 
antibodies specific for the recombinant protein of extracellular domain of the Her-2/neu receptor. 
Results: Serum samples from 12 patients with benign changes in mammary glands (the first 
group) and 49 breast cancer patients with 1-3 stages of the disease (the second group) were used in 
this study. In the first group, the average level of Her2/neu in serum was 8.5 ng/ml (ranging 5-12.5 
ng/ml), while in the second group this indicator was 55 ng/ml (ranging 17.5-92.5 ng/ml). The broad 
range of oncological marker variation in the second group is attributable to cancer stages (1 through 
3). Thus, the average concentration of the oncoprotein in patients at cancer stages 2 and 3 was -
72.5 ng/ml compared to patients with 1 stage where the mean was - 29.5 ng/ml. 
Conclusion: Identification of circulating extracellular domain of Her2/neu oncoprotein in 
serum is a non-invasive tool for early prognosis of breast cancer. Developed ELISA on the basis of 
monoclonal antibodies could help choose an appropriate treatment strategy and manage patients 
health condition after treatment. 
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